In clinical practice, personalized medicine refers to the use of new methods of molecular analysis to better manage a patient's disease or predisposition towards a disease. It aims to achieve optimal medical outcomes by helping physicians and patients choose the disease management approaches likely to work best in the context of a patient's genetic and environmental profile.

The future of cancer treatment, prevention and detection will be guided by the use of more effective cancer biomarkers. New biomarkers that help to target and monitor therapy are continuing to emerge as the path forward on the best way to integrate them into clinical practice and regulatory strategies evolves. Ultimately, biomarkers have the potential to spur innovation, streamline the development process and help patients by providing treatment tailored to their genetic makeup.

Amgen is applying the use of cutting-edge science and technology to make earlier, better, more informed decisions in its development of cancer therapeutics. We are committed to leveraging our understanding of pharmacogenomics and cancer biology in the Research & Development process.